Stocks · News reference
Why Is Contineum Therapeutics Stock Falling Monday?
BMS trial results trigger a 29% drop in Contineum (CTNM), but analysts highlight long-term potential for PIPE-791 in IPF.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BlackLine Honors Global Enterprise Leaders Transforming Financial Operations
BlackLine announced its 2026 Modern Accounting Awards, honoring six enterprise leaders—Booking Holdings, Bristol Myers Squibb, James Hardie, LAZ Parking, Payoneer, and US Foods—for redefining financial operations through unified data architectures, intelligent automation, and agentic workflows. These organizations have eliminated tens of thousands of manual close hours and established continuous, audit-ready financial operations.
Bristol-Myers Squibb shares are trading higher after the company announced results from unit RayzeBio's ACTION-1 trial of RYZ101, which study met its primary endpoint with statistically significant and clinically meaningful improvement in progression-free survival with consistent safety results.
Jones Trading Maintains Buy on Contineum Therapeutics, Raises Price Target to $30
This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded CTNM, CC, ACI, BRKR and SAFE; targets fell for CTNM, CC and ACI, while BRKR received a new $60 target.
Baird Downgrades Contineum Therapeutics to Neutral, Lowers Price Target to $14
Baird analyst Joel Beatty downgrades Contineum Therapeutics (NASDAQ:CTNM) from Outperform to Neutral and lowers the price target from $19 to $14.